Publications

Selected most Relevant Publications

  1. New England Journal of Medicine. 2010; 362(14): 1348-1350.
  2. Diabetes Care. 2010, 33(2): 290-293.
  3. Molecular Endocrinology, 2009; 23(12):1983–1989
  4. Diabetes. 2004; 53(8):2164-8.
  5. Diabetes. 2002;51(4):1240-6.
  6. New England Journal of Medicine, 2001; 344 (21): 1588-1592.
  7. Diabetologia, 2001; 44: 898-905.
  8. Diabetologia; 1999. 42:1175-1186.
  9. Diabetes. 1999. 48:1698-1705.
  10. New England Journal of Medicine. 1998. 22; 338(4): 226-30

Publications

  • Luis Miguel Álvarez-Aragón, Antonio Luis Cuesta-Muñoz, Inmaculada Álvarez-López. Inquiring into Benefits of Independent Activation of Non-Classical Renin-Angiotensin System in the Clinical Prognosis and Reduction of COVID-19 mortality. Clin Infect Dis. 2020 Apr 8: ciaa402.
  • Francisca Beatriz Rivas-Sánchez, Estíbaliz Romero-Masa, María Rocío Pacheco-Yepes, Antonio Luis Cuesta-Muñoz, Ricardo Gómez- Huelgas. Diabetes rápidamente progresiva como primera manifestación de un adenocarcinoma de páncreas. Rev Esp Casos Clin Med Intern (RECCMI). 2017 (Ago); 2(2): 68-70
  • Gavito AL, Bautista D, Suarez J, Badran S, Arco R, Pavón FJ, Serrano A, Rivera P1, Decara J, Cuesta AL, Rodríguez-de-Fonseca F, Baixeras E. Chronic IL-6 Administration Desensitizes IL-6 Response in Liver, Causes Hyperleptinemia and Aggravates Steatosis in Diet-Induced-Obese Mice. PLoS One. 2016; 22; 11(6).
  • Gavito AL, Cabello R, Suarez J, Serrano A, Pavón FJ, Vida M, Romero M, Pardo V, Bautista D, Arrabal S, Decara J, Cuesta AL, Valverde AM, Rodríguez de Fonseca F, Baixeras E. Single administration of recombinant IL-6 restores the gene expression of lipogenic enzymes in liver of fasting IL-6-deficient mice. Br J Pharmacol. 2016; 173(6):1070-84.
  • Gomez-Huelgas R, Narankiewicz D, Villalobos A, Wärnberg J, Mancera-Romero J, Cuesta AL, Tinahones FJ, Bernal-Lopez MR. Prevalence of Metabolically Discordant Phenotypes in a Mediterranean Population. The Imap Study. Endocr Pract. 11:1-33. 2013.
  • Vida M, Serrano A, Romero-Cuevas M, Pavón FJ, González-Rodriguez A, Gavito AL, Cuesta AL, Valverde AM, Rodríguez de Fonseca F, Baixeras E.IL-6 cooperates with peroxisome proliferator-activated receptor-α-ligands to induce liver fatty acid binding protein (LFABP) up-regulation. Liver Int. 33(7):1019-28. 2013
  • Bernal-Lopez MR, Santamaría-Fernandez S, Lopez-Carmona D, Tinahones FJ, Mancera-Romero J, Peña-Jimenez D, Jansen-Chaparro S, Baca-Osorio AJ, Cuesta-Muñoz AL, Serrano-Rios M, Gomez-Huelgas R. A1C in adults without known diabetes from southern Europe. Impact of the new diagnostic criteria in clinical practice. Diabetic Medicine. 2011; 28(11):1319-22.
  • Sameer Kassem, Sonal Bhandari, Pablo Rodríguez-Bada, Nadia Cobo-Vuilleumier, Roja Motaghedi, Maayan Heyman, M. Adelaida García- Gimeno, Pascual Sanz, Noel K. Maclaren, Jacques Rahier, Benjamin Glaser, and Antonio Luis Cuesta-Muñoz. Large Islets, Beta-Cell Proliferation, Hypoglycemia and a Glucokinase Mutation.  New England Journal of Medicine. 2010; 362(14): 1348-1350.
  • Cuesta-Muñoz AL, Tuomi T, Cobo-Vuilleumier N, Koskela H, Odili S, Stride A, Buettger C, Otonkoski T, Froguel P, Grimsby J, Garcia-Gimeno M, Matschinsky FM. Clinical Heterogeneity in Monogenic Diabetes Caused by Mutations in the Glucokinase Gene (GCK-MODY). Diabetes Care. 2010, 33(2): 290-293.
  • Barbetti F, Cobo-Vuilleumier N, Dionisi-Vici C, Toni S, Ciampalini P, Massa O, Rodriguez-Bada P, Colombo C, Lenzi L, Garcia-Gimeno MA, Bermudez-Silva FJ, Rodriguez de Fonseca F, Banin P, Aledo JC, Baixeras E, Sanz P, Cuesta-Muñoz AL. Opposite clinical phenotypes of glucokinase disease: Description of a novel activating mutation and contiguous inactivating mutations in human glucokinase (GCK) gene. Molecular Endocrinology, 2009; 23(12):1983–1989
  • Meissner T, Marquard J, Cobo-Vuilleumier N, Maringa M, Rodríguez-Bada P, García-Gimeno MA, Baixeras E, Weber J, Olek K, Sanz P, Mayatepek E, Cuesta-Muñoz AL. Diagnostic difficulties in glucokinase hyperinsulinism. Horm Metab Res., 2009; 41(4):320-6.
  • Aledo JC, Jiménez-Rivérez S, Cuesta-Munoz A, Romero JM. The role of metabolic memory in the ATP paradox and energy homeostasis. FEBS J. 2008; 275(21):5332-42.
  • Cahuana GM, Tejedo JR, Hmadcha A, Ramírez R, Cuesta AL, Soria B, Martin F, Bedoya FJ.. Nitric oxide mediates the survival action of igf-1 and insulin in pancreatic β-cells. Cell Signalling. 2008; 20(2):301-310
  • F.J. Bermúdez-Silva, J. Suárez, E. Baixeras, N. Cobo, D. Bautista, A.L. Cuesta-Muñoz, E. Fuentes, P. Juan-Pico, M.J. Castro, G. Milman, R. Mechoulam, A. Nadal and F. Rodríguez de Fonseca. Presence of functional cannabinoid receptors in human endocrine pancreas.  Diabetologia. 2008; 51(3): 476-487
  • Antonio L. Cuesta Muñoz and  Nadia Cobo Vuilleumier. Hiperinsulinismo Monogénico. Avances en Diabetología. 2007; 23(5): 350-357
  • Montero F, Baglietto-Vargas D, Moreno-González I, López-Tellez JF, Cuesta-Munoz AL, Gutiérrez A, Aledo LC. Glutaminase activity is confined to the mantle of the islets of Langerhans. Biochimie. 2007; 89:1366-1371
  • A L. Cuesta-Munoz.Diabetes Monogénicas.En Tratado SED de Diabetes Mellitus. Bases moleculares, clínicas y tratamiento. 2007; Pag 47. Editorial Médica Panamericana.
  • A L. Cuesta-Munoz.Diabetes Monogénicas.En Tratado SED de Diabetes Mellitus. Bases moleculares, clínicas y tratamiento. 2007; Pag 47. Editorial Médica Panamericana.
  • A L. Cuesta-Munoz.Diabetes Monogénicas.En Tratado SED de Diabetes Mellitus. Bases moleculares, clínicas y tratamiento. 2007; Pag 47. Editorial Médica Panamericana.
  • Leda Pedelini, Maria Adelaida Garcia-Gimeno, Alberto Marina, Juan M. Gomez-Zumaquero, Pablo Rodriguez-Badía, Soledad López-Enriquez, Federico C. Soriguer, Antonio L. Cuesta-Muñoz and Pascual Sanz. Structure-function analysis of alpha5 and alpha13 helices of human glucokinase: description of two novel activating. Protein Science 2005;14(8):2080-6.
  • Antonio Luis Cuesta Muñoz. Persistent Hyperinsulinemic Hypoglycemia. Encyclopedic Reference of Molecular Mechanisms of Disease. 2004. Editores: Springer-Verlag
  • Antonio Luis Cuesta Muñoz. Defectos genéticos de la glucocinasa y alteraciones del metabolismo hidrocarbonado.Endocrinología y Nutrición, Monográfico. 2004
  • Cuesta-Munoz AL, Huopio H, Otonkoski T, Gomez-Zumaquero JM, Nanto-Salonen K, Rahier J, Lopez-Enriquez S, Garcia-Gimeno MA, Sanz P, Soriguer FC, Laakso M. Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation. Diabetes. 2004; 53(8):2164-8.
  • A.L. Cuesta y Soria B.Transplante de islotes pancreáticos y obtención de células productoras de insulina a partir de células troncales. Cardivascular Risk Factors. 2004; 13(4): 237-242
  • Soriguer F, Moreno F, Rojo-Martinez G, Garcia-Fuentes E, Tinahones F, Gomez-Zumaquero JM, Cuesta-Munoz AL, Cardona F, Morcillo S. Monounsaturated n-9 fatty acids and adipocyte lipolysis in rats. Br J Nutr. 2003;90(6):1015-22.
  • Christesen HB, Jacobsen BB, Odili S, Buettger C, Cuesta-Munoz A, Hansen T, Brusgaard K, Massa O, Magnuson MA, Shiota C, Matschinsky FM, Barbetti F. The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy. Diabetes. 2002;51(4):1240-6.
  • Soriguer-Escofet F, Esteva I, Rojo-Martinez G, Ruiz de Adana S, Catala M, Merelo MJ, Aguilar M, Tinahones F, Garcia-Almeida JM, Gomez-Zumaquero JM, Cuesta-Munoz AL, Ortego J, Freire JM; Diabets Group of the Andalusian Society of Endocrinology and Nutrtion. Prevalence of latent autoimmune diabetes of adults (LADA) in Southern Spain. Diabetes Res Clin Pract. 2002;56(3):213-20.
  • Graeme I. Bell, Antonio Cuesta Muñoz and Franz M. Matschinsky.Glucokinase. En la “Wiley Encyclopedia of Molecular Medicine”; 2002: 1437-1440 Editorial: Ed. Thomas E. Creighton. John Wiley and Sons, Inc, New York.
  • Pal R. Njolstd, Oddmund Sovik, Antonio Cuesta Muñoz, Lise B. Gundersen, Anders Molven, Dag Undlien, Mark A. Magnuson, Franz Matschinsky and Graeme I. Bell. Permanent neonatal diabetes mellitus due to complete glucokinase deficiency. New England Journal of Medicine, 2001; 344, Nº21: 1588-1592.
  • Massa, F Meschi, A Cuesta-Muñoz, A Caumo, F Cerutti, S Toni, V Cherubini, L Guazzarotti, N Sulli, FM Matschinsky, R Lonini, D Iafusco, F Barbetti and the Diabetes Study Group of the Italian Society of Pediatric Endocrinology and Diabetes (SIEDP). High prevalence of glucokinase mutations in Italian children with MODY. Influence on Glucose Tolerance, Fisrt-Phase Insulin Response, Insulin Sensitivity and BMI. Diabetologia, 2001; 44: 898-905.
  • Cuesta-Munoz A, Buettger C, Davis E, Shiota C, Magnuson MA, Grippo JF, Grimsby J, Matschinsky FM. Novel pharmacological glucokinase activators partly or fully reverse the catalytic defects of inactivating glucokinase missense mutations that cause MODY-2.  Diabetes 2001; 50:A109-110.
  • Shah N, Zelent D, Najafi H, Burke C, Raper S, Cuesta-Munoz AL, Matschinsky FM, Jarett L. Electron microscopic demonstration of glucokinase in insulin granules of rat pancreatic beta cells. Diabetes 2001; 50: A353-A354.
  • Franz M. Matschinsky, Antonio Cuesta-Muñoz, Elizabeth Davis, Carol Buettger, Ian Sweet, Michael Moates, and Mark A., Magnuson. The Glucokinase System and the Regulation of Blood Sugar. Frontiers in Diabetes Molecular  Pathogenesis of MODYs. Editores: Matschinsky FM, Magnuson MA. Clave: CL Año: 2000    Volumen 15  Páginas: Editorial: F. Belfiore. Karger. Basilea (Suiza)
  • Weber IT, Harrison RW, Cuesta-Munoz A., Davis E, Matschinsky FMT. Molecular modeling of human glucokinase: Implications for the activity of mutants. Frontiers in Diabetes Molecular  Pathogenesis of MODYs. Nombre del editor en su caso: Matschinsky FM, Magnuson MA. Clave: CL    Año: 2000    Volumen:   Páginas: Editorial: F. Belfiore. Karger  (Suiza)
  • E.A. Davis, A. Cuesta Muñoz, M. Raoul, C.W. Buettger, I. Sweet, M. Moates, M.A. Magnuson, F.M. Matschisky.Mutants of Glucokinase cause hypo and hyperglycemia Syndromes and their analisis iluminates fundamental quantitative concepts of glucose homeostasis. Diabetologia; 1999. 42:1175-1186.
  • B. Mahalingam, A. Cuesta Muñoz, E.A. Davis, F.M. Matschisky, R.W. Harrison, Irene T Weber. Model in Human Glucokinase in complex with Glucose and ATP: Implications for mutants that cause hypo and hyperglycemia. Diabetes. 1999. 48:1698-1705.
  • Glaser,B; Kesavan,P; Heyman,M; Davis, E; Cuesta, A; Buchs,A; Stanley,CA; Thornton,PS; Permutt,MA; Matschinsky,FM; Herold, KC. Familial hyperinsulinism caused by an activating glucokinase mutation. New England Journal of Medicine. 1998. 22; 338(4): 226-30.
  • Kasavan, E.A. Davis, A. Cuesta Muñoz, I. Sweet, K. Niswender, Mark Magnuson and Franz Matschisky. Structural instability of mutant β-cell Glucokinase: implications for the molecular patogenesis of maturiry-onset diabetes of the young (type-2). Biochemical Journal. 1997; 322: 57-63.
  • Cuesta Muñoz, Antonio, M. Revilla, L.F. Villa, E.R. Hernandez, H. Rico. Total and regional bone mineral content in Spanish professional ballet dancers. Calcified Tissue International. 1996; 58:150-154
  • Soria, P., A. Cuesta, H. Romero, F.J. Martinez, A. Sastre. Dietary treatment of Limphoedema by restriction of long-chain triglycerides Angiology. 1994; 45:703- 707.
  • Cuesta Muñoz, A.L., M. Revilla, A.Sastre Gallego. Calcio y composición corporal en los bailarines profesionales.Alimentación, Nutrición y Salud . 1994; 1:2-6.
  • Cuesta Muñoz, A.L. Dietary intake and body composition in professional ballet dancers. International Journal of Sport Medicine. 1993; 14 (5):293-294
  • Vidal Puig, A. Cuesta Muñoz, A.L., Hernaez Ugarte, I., A.Sastre Gallego. Principios generales para la correcta alimentación del paciente con diabetes mellitus. Nutrición Clínica. 1993; 13: 21-28.

Lectures

  • Patients with Elevated GCK Have More SST Cells. 77st Scientific Sessions of the American Diabetes Association. June 2017. San Diego, USA.
  • Patients with Overactivated GCK Have More SST Cells and… ӦRESUND ISLET STUDY GROUP. Workshop on “Islet Cell Plasticity”. Faculty Club, Panum Institute. June 2017. Copenhagen, Denmark.
  • Glucokinase gene mutations and Diabetes. New Horizons on Diabetes Therapy. Universidade Estadual de Campinas – UNICAMP, 18 de Maio de 2016. Brasil
  • Keynote Lecture. From Monogenic Beta-Cell Defects Straight to Pharmacogenetics. 1st PHARMACOGENOMICS İSTANBUL SUMMIT, Increasing the Safety and Effectiveness of Personalized Therapy for Metabolic Disorders. European Society of Pharmacogenomics and Personalised Therapy (ESPT). 27-28 November, 2015. İstanbul, Turkey.
  • Activating glucokinase gene mutations: From human model to cell therapy? Danish Diabetes Academy. Panum Institute. Copenhagen. Denmark. October 2013.
  • Highly efficient human islets due to activating glucokinase gene mutations: lessons from human models. EASD Islet Study Group – Rostock, Alemania October 2012.
  • Glucokinase Gene Activation and Highly Efficient Human Islets: Lessons from Human Models. 72st Scientific Sessions of the American Diabetes Association. June 2012. Filadelfia, USA.
  • Monogenic Diabetes, genetic analysis. When should be done? 54 Meeting of the Spanish Society of Endocrinology and Nutrition. Mayo 2012, Oviedo, Spain.
  • Monogenic Diabetes, how to identify and treat them. VI Reunión de Diabetes y Obesidad, SEMI, Enero 2012, Zaragoza, Spain.
  • Replication of Beta cell Proliferation in Islets Containing the Naturally Occurring Activating Glucokinase Gene Mutation V91L. Implications for Cell Therapy. Workshop: Programming Beta Cell Development, Impairment and Regeneration 23-26 October 2011, LO-skolen, Helsingør, Denmark
  • Human Islets Proliferation and Glucokinase Mutations “The Genetics of Diabetes in the Post-Genome Wide Association Era” 3rd Biannual Congress of EASD-SGGD. September 30th – October 2nd, 201. Smolenice Castle, Bratislava, Slovakia
  • Impact of naturally occurring severe activating glucokinase mutation gene in human islets. 21th EASD- Islets Study Group. May, 8 – 11, 2011. Natal, Rio Grande do Norte, Brazil
  • Glucokinase and Highly Efficient Islets; The paradox of how hypoglycaemia can help hyperglycemia. 2 Ulusal Hücresel Tedavi ve Rejenerative Tip Kongresi. Izmir, Turkey 11-13 Febrero 2011
  • Large Islets, Beta-Cell Proliferation and a Glucokinase Mutation. The paradox of how hypoglycaemia can help hyperglycemia. “Cell Transplant Center Research Conference” Diabetes Research Institute (DRI). Univeristy of Miami Leonard M. Miller School of Medicine June 30, 2010. Miami, FL. USA
  • Large Islets, Beta-Cell Proliferation and a Glucokinase Mutation. Instituto de Biomedicina de Valencia (CSIC). Abril 2010.Valencia, Spain.
  • Glucokinase Hypoglycemia. “Fundamentos Moleculares de la Medicina” Real Academia Nacional de Medicina. 6-7 Mayo, 2009 Madrid, Spain.
  • Glucokinase and hypoglycemia. Second Meeting of the EASD Study Group on Genetics of Diabetes (EASD-SGGD). Bergen, Norway. April 2009.
  • Monogenic Diabetes. XXIII Curso de Endocrinología para Postgrado 2008. Sociedad Española de Endocrinología y Nutrición. 9-11 Marzo 2008. Madrid, Spain.
  • Clinical and pharmacological spectrum of GCK activating mutation. First Meeting of the EASD Study Group on Genetics of Diabetes (EASD-SGGD) 4 y 5 de Octubre 2007. Málaga, Spain.
  • Monogenic Pancreatic b-cell Disease. International Symposium “Bioengineering of Pancreatic Islet”  CABIMER 11th-12th January 2007 Sevilla, Spain.
  • Monogenic Diabetes and Pharmacogenetics. II Official Joint Meeting ADA – SED Septiembre de 2006. Madrid, Spain.
  • “Clinical and molecular aspects of the Familial Hyperinsulinism due to Glucokinase” Activating Mutations. International symposium: “Congenital hyperinsulinism and related disorders of insulin secretion:  Clinical, biochemical and genetic advances”. Philadelphia, USA. June 15-16, 2006.
  • Keynote Lecture. Activating Mutations in glucokinase gene and glucose homeostasis. XVIII Scientific Meeting of the Spanish Diabetes Society. Febrero de 2006. Madrid, Spain.
  • “Is glucokinase a target only for treatment of type 2 diabetes?” some considerations.  European Islets Study Group (EASD). Noviembre 11 – 12, 2005. Alicante, Spain.
  • “Glucokinase disease. clinical diagnosis, functional studies and something else”. University Medical Centre of Geneva, Switzerland 9 de mayo 2005. Geneva, Switzerland.
  • “Heterogenous hyperinsulinemic phenotype of glucokinase disease.” Managing Beta-cell Diseases in the Postgenomic Era:  First Meeting of the European Group for the Study of Monogenic Diabetes. 21-22 Octubre del 2004. Málaga, Spain.
  • “Glucokinase, anithing else?. Should “MODY” stand for maturity onset diabetes of the young?”.  Diabetes and Vascular Medicine
  • Molecular Genetics Laboratory, Royal Devon& Exeter Hospital, Exeter, England. 28 de Abril de 2004. Exeter, England.
  • “Glucokinase disease. should “mody” stand for maturity onset diabetes of the young?”. Children’s Hospital of Pittsburgh, General Clinical Research Center and University of Pittsburgh School of Medicine. 14 Noviembre 2003. Pittsburg. Pennsylvania, USA.
  • Keynote Lecture. “Diabetes tipo 2 y mody en el adolescente”.1ª Jornadas de Endocrinología Pediátrica del Hospital Dona Estefanía. Título: Mayo 2003, Lisboa, Portugal.
  • “Molecular Bases of Diabetes MODY”. XVI Scientific Meeting of the Spanish Diabetes Society 2 – 5 Marzo, 2002.  Cádiz, Spain
  • «Glucokinase, from basics to therapeutics. Why?”. Scientific Sessions on Diabetes. Novo Nordisk. 24 Septiembre, 2001. Compenhagen, Denmark.

Scientific Workshop/meetings

  • President of the Organizing and Scientific Committee of the First Meeting of the European Group for the Study of Monogenic Diabetes: Managing Beta-cell Diseases in the Postgenomic Era. 2002 Malaga, Spain.
  • Member of the Organizing and Scientific Committee of the XVII Scientific meeting of the Spanish Diabetes Society 2004, Valencia, Spain.
  • Member of the Organizing and Scientific Committee of the XVIII Scientific Meeting of the Spanish Diabetes Society 2005, Madrid, Spain.
  • Member of the Organizing and Scientific Committee of the II Meeting of the Spanish Diabetes Society 2005, Zaragoza, Spain.
  • President of the Organizing and Scientific Committee of the First Meeting of the EASD Study Group on Genetics of Diabetes (EASD-SGGD) 2007. Málaga, Spain.
  • Member of the Organizing and Scientific Committee of the Second Meeting of the EASD Study Group on Genetics of Diabetes (EASD-SGGD). 2009. Bergen, Norway. April.
  • Member of the Organizing and Scientific Committee of the 3rd Biannual Congress of EASD-SGGD. “The Genetics of Diabetes in the Post-Genome Wide Association Era” 2011. Bratislava, Slovakia.